Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Medivolve Inc MEDVF

Medivolve Inc. is a Canadian healthcare technology company. The Company and its subsidiaries, Medivolve Pharmacy Inc. (doing business as Marbella Pharmacy) and Kedy Ying Jao D.O., a Medical Corporation, operate a distributed network of two retail patient-care locations in California, United States. It has two business units: Medivolve Pharmacy Division (MPD) and Medivolve Clinic Services Division (MCSD). MPD provides retail pharmacy and mail-order pharmacy services related to COVID-19, antibiotics, dermatology, family medicine, immunology, neurology, pain management, pediatrics, preventive medicine and psychiatry to patients in Southern California. MCSD provides licensed healthcare through a clinic in Brea, California, United States. MCSD is focused on developing a telehealth platform, which connects patients with physicians, and facilitates and manages the provision of virtual consultation, diagnosis, and treatment services in partnership with qualified health practitioners.


OTCPK:MEDVF - Post by User

Comment by Knowsitallon Nov 26, 2021 8:11am
109 Views
Post# 34167903

RE:RE:RE:MEDV is Creating value. FACT

RE:RE:RE:MEDV is Creating value. FACT
GeneralWolfe wrote: NO, not the case at all. You are lying again... lolll, but nice try. Again, just facts. Some of the MEDV highlights from the zoom call. -Share Consolidation Passed - R/S was addressed and is “only” if needed to uplist but is not a priority they feel they can hit targets based on increasing and projected revenue going into 2022 -They are on pace for their projected revenue of 60M for 2021 (*From invester deck, looking at Q3 we could very well pass 60 million) -Spoke on Q4: "We anticipate to be just as good if not significantly better than Q3, trend it going in the right direction. Maybe a dip in November, fluctuation of business (10-15% dip from absolute peak)." *Q3 Revenue was $25.3 Million -Spoke to their software ,Govt asking for even more testing, different tests coming at locations, influenza and other tests, Focusing on expanding platforms with AI , Cholesterol and diabetes tech, prescriptions. -States MEDV is grossly undervalued, Says to deal with shorts by producing revenue results and increasing them.


I like you NAME  GeneralWolfe ..Tell us more about it . The origin the reason ,the history behind it. FACTS vs THEORY VS wishfull thinking VS BS ??????
<< Previous
Bullboard Posts
Next >>